Analysis Of Ferritin Expression In Patients With Hepatocellular Carcinoma And Clinical Significance Of Iron Lowering Drugs In Inhibiting Hepatocellular Carcinoma

BackgroundPrimary liver cancer,or liver cancer,is characterized by high incidence rate and high mortality rate.The new and death cases of liver cancer in China are ranked first in the world.The current clinical treatment methods for liver cancer include surgical resection,liver transplantation and transcatheter arterial chemoembolization.The incidence of liver cancer is more hidden,most of the patients have been diagnosed as late and middle-term,and the five-year survival rate is still low.Iron is one of the essential nutrients in human body,which plays an important role in maintaining the stability of the environment in the machine.Iron in the body mainly comes from food.A large number of literature reported that iron is related to the development of tumor;Clinical data showed that iron metabolism was abnormal in patients with liver cancer.It is reported that 45.1% of 204 patients with liver cancer have iron deposition in liver,and the iron deposition in the manifold area is closely related to tumor invasion.Ferritin is a protein with iron storage function in the body,including H-chain(heavy chain)and L-chain(light chain)subunits.This study analyzed the correlation between ferritin heavy chain(FTH1)and light chain(FTL)and the occurrence and prognosis of liver cancer by clinical database,and discussed the effect of reducing the iron content of hepatoma cells on the proliferation of tumor.The purpose of this study is to guide the patients to take iron reasonably and provide clinical nursing basis for the application of iron reducing drugs.ObjectiveObjective to obtain the clinical data of patients with liver cancer by searching the Cancer Genome Atlas(TCGA)database,analyze the difference of the expression of FTH1 and FTL between patients with liver cancer and healthy people,and the correlation between the expression of FTH1 and FTL and the survival time of patients with liver cancer,objective to provide the basis for the correct guidance of iron intake in patients with liver cancer and the clinical application of iron reducing drugs.Methods1.Search TCGA database and collect the clinical data of patients with liver cancer,analyze the expression difference of ferritin FTH1 and FTL in liver cancer tissue and normal liver tissue,and the correlation with the survival time of patients with liver cancer.Spss22.0 statistical software was used for statistical description,independent sample u test and Kaplan Meier analysis.2.The effect of desferrioxamine(DFO)on the level of labile iron pool(LIP)in hepatoma cells was detected by calcein spectrophotometry.Spss22.0 statistical software was used for statistical analysis and independent sample t test.3.The effects of DFO on the proliferation and clonal ability of Hep G2 and Huh7 cells were detected by CCK-8,plate clone experiment and real-time unmarked cell analyzer.Spss22.0 software was used to analyze the data,t test of independent samples and single factor variance analysis.Results1.The results of clinical data analysis showed that the expression of FTH1 and FTL in liver ancer tissues was significantly higher than that in normal liver tissues,suggesting that the level of ferritin in patients with liver cancer was higher;the high expression of ferritin FTH1 was negatively correlated with the survival time of patients with liver cancer.2.Calcein spectrophotometry was used to determine the effect of iron reducing drug DFO on the content of LIP in human hepatoma cells.The results showed that the content of LIP in hepatoma cells treated with DFO was significantly lower than that in the control group,indicating that DFO can reduce the content of free iron in hepatoma cells,suggesting that iron reducing drugs can effectively reduce the iron load in human hepatoma cells(P<0.01).3.CCK-8 results showed that compared with the control group,DFO significantly inhibited the proliferation of hepatoma cells(P<0.05),and the inhibition rate increased with the increase of drug concentration,which was concentration and time-dependent.According to the results of CCK-8,the optimal concentration of DFO was 25umol/L,and the optimal time was 48 h.The results of plate cloning showed that the number of hepatoma cells in DFO group was significantly reduced,and DFO could effectively reduce the cloning ability of hepatoma cells(P<0.05);The results of 96 h continuous monitoring by real-time label free cell analyzer showed that compared with the control group,the proliferation ability of liver cancer cells in DFO group gradually weakened with the extension of time.Conclusion1.The levels of ferritin FTH1 and FTL in liver cancer were significantly higher than those in normal liver tissues,and there was a negative correlation between ferritin FTH1 and the prognosis of patients with hepatocellular carcinoma;2.DFO can significantly reduce the iron load in hepatoma cells;3.DFO can significantly inhibit the proliferation of hepatoma cells.